Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.49 |
| ▸ | PPARG | P37231 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437283 | 0.85 | KMT2A (0.40) | PPARAPPARGKMT2AKDM4EGFER | |
| SCHEMBL6073125 | 0.78 | PPARA (0.51) | PPARAPPARGKMT2ACYP2C9KDM4E | |
| SCHEMBL6073209 | 0.77 | PPARA (0.50) | PPARAPPARGKMT2AKDM4EGFER | |
| SCHEMBL5431707 | 0.75 | PPARA (0.50) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL5441860 | 0.74 | PPARA (0.56) | PPARAPPARGNPSR1 | |
| SCHEMBL5935712 | 0.73 | ALDH1A1 (0.44) | KMT2AKDM4EATMGAA | |
| SCHEMBL6073213 | 0.73 | LMNA (0.46) | PPARAPPARGKMT2AKDM4EGFER | |
| SCHEMBL5423669 | 0.72 | PPARA (0.54) | PPARAPPARGKMT2AKDM4ETP53 | |
| SCHEMBL5424327 | 0.72 | PPARA (0.48) | PPARAPPARGCYP2C9KCNH2KDM4E | |
| SCHEMBL13717743 | 0.71 | PPARA (0.61) | PPARAPPARGCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | PPARA 990/4885PPARG 615/4885KMT2A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.